Geode Capital Management LLC boosted its holdings in shares of Celcuity Inc. (NASDAQ:CELC – Free Report) by 9.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 692,372 shares of the company’s stock after purchasing an additional 62,003 shares during the period. Geode Capital Management LLC owned 1.86% of Celcuity worth $9,065,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its position in Celcuity by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company’s stock worth $21,624,000 after purchasing an additional 24,429 shares during the last quarter. State Street Corp increased its position in Celcuity by 152.2% in the third quarter. State Street Corp now owns 1,107,415 shares of the company’s stock worth $16,512,000 after purchasing an additional 668,318 shares during the period. Artisan Partners Limited Partnership raised its holdings in Celcuity by 18.2% during the 4th quarter. Artisan Partners Limited Partnership now owns 491,507 shares of the company’s stock worth $6,434,000 after purchasing an additional 75,830 shares during the last quarter. Candriam S.C.A. bought a new stake in Celcuity during the 4th quarter worth about $3,450,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Celcuity by 7.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 237,706 shares of the company’s stock valued at $3,112,000 after purchasing an additional 16,035 shares during the period. 63.33% of the stock is owned by institutional investors.
Celcuity Trading Down 0.4 %
CELC opened at $11.07 on Thursday. The firm’s fifty day moving average is $10.22 and its two-hundred day moving average is $12.26. The firm has a market cap of $418.88 million, a PE ratio of -4.24 and a beta of 0.44. Celcuity Inc. has a twelve month low of $7.58 and a twelve month high of $19.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on CELC shares. Needham & Company LLC reissued a “buy” rating and set a $29.00 price target on shares of Celcuity in a research note on Friday, April 11th. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Celcuity in a research report on Tuesday, April 1st. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $30.17.
View Our Latest Stock Analysis on Celcuity
Celcuity Profile
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
See Also
- Five stocks we like better than Celcuity
- What Are Dividend Achievers? An Introduction
- Can IBM’s Q1 Earnings Spark a Breakout for the Stock?
- The 3 Best Retail Stocks to Shop for in August
- S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Fundamentally Sound, These 5 Stocks Sold Off Anyway
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.